Announcement Summary

Name of entity

MAYNE PHARMA GROUP LIMITED

Announcement type

Update announcement

Type of update

☑ Final buy-back notification

Date of this announcement

3/4/2023

Reason for update

Final buy-back notification

ASX Security code and description of the class of +securities the subject of the buy-back

MYX : ORDINARY FULLY PAID

The type of buy-back is:

☑ Employee share scheme buy-back

Total number of +securities bought back

702,163

Total consideration paid or payable for the securities

0.00000

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) provide the following information about our buy-back.

1.2 Registration number type

ACN

Registration number

115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

☑ Update/amendment to previous announcement

1.4a Type of update

☑ Final buy-back notification

1.4b Reason for update

Final buy-back notification

1.4c Date of initial notification of buy-back

30/3/2023

1.4d Date of previous announcement to this update

3/4/2023

1.5 Date of this announcement

3/4/2023

1.6 ASX Security code and description of the class of +securities the subject of the buy-back

MYX : ORDINARY FULLY PAID

Part 2 - Type of buy-back

2.1 The type of buy-back is:

☑ Employee share scheme buy-back

Part 3 - Buy-back details

Part 3A - Details of +securities, price and reason

3A.1 Total number of +securities on issue in the class of +securities to be bought back

85,776,451

3A.2 Total number of +securities proposed to be bought back

702,163

3A.9 Are the +securities being bought back for a cash consideration?

☑ No

3A.9b Please describe the consideration being provided to buy back the +securities

Extinguishment of employee share loans totalling $10,700,964 originally advanced by the Company to the employees concerned for the purchase of the loan scheme shares being cancelled. No cash is payable by the Company for the buy back.

Part 3B - Buy-back restrictions and conditions

3B.1 Does the buy-back require security holder approval?

☑ No

3B.3 Are there any other conditions that need to be satisfied before the buy-back offer becomes unconditional?

☑ No

Part 3C - Key dates

Employee Share Scheme, Selective and Other Buy-Backs

3C.1 Anticipated date buy-back will occur

31/3/2023

Part 3D - Other Information

3D.1 Any other information the entity wishes to notify to ASX about the buy-back

In accordance with the terms of the Mayne Pharma Group Employee Loan plan, the Company is buying back and cancelling employee loan shares that have reached the grant expiry date and become forfeited shares as the performance conditions were not met or the share price was lower than the issue price of the shares. These shares were issued to employees in 2018.

Part 5 - Final buy-back notification

For on-market buy-backs, a final buy-back notification must be submitted at least half an hour before the commencement of trading on the business day after the company buys back the maximum number of securities that it wanted or the company decides it will stop buying back securities.
For equal access buy-back schemes, a final buy-back notification must be submitted no later than five business days after the buy-back offer closing date.
For employee share scheme buybacks, selective buy-backs and other buy-backs, a final buy-back notification must be submitted by no later than five business days after the completion of the buy-back.

5.1 Total number of +securities bought back

702,163

5.2 Total consideration paid or payable for the securities

0.00000